ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
256.96
+1.08 (0.42%)
Jul 3, 2025, 1:00 PM - Market closed
ResMed Stock Forecast
Stock Price Forecast
The 12 analysts that cover ResMed stock have a consensus rating of "Buy" and an average price target of $259.4, which forecasts a 0.95% increase in the stock price over the next year. The lowest target is $180 and the highest is $290.
Price Target: $259.4 (+0.95%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 24, 2025.
Analyst Ratings
The average analyst rating for ResMed stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Hold | 6 | 5 | 5 | 5 | 5 | 4 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $247 → $255 | Hold | Maintains | $247 → $255 | -0.76% | Apr 24, 2025 |
| UBS | UBS | Strong Buy Maintains $290 → $285 | Strong Buy | Maintains | $290 → $285 | +10.91% | Apr 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $286 → $290 | Buy | Maintains | $286 → $290 | +12.86% | Apr 24, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $260 → $248 | Hold | Maintains | $260 → $248 | -3.49% | Apr 24, 2025 |
| Keybanc | Keybanc | Buy Maintains $269 → $274 | Buy | Maintains | $269 → $274 | +6.63% | Apr 24, 2025 |
Financial Forecast
Revenue This Year
5.17B
from 4.69B
Increased by 10.37%
Revenue Next Year
5.57B
from 5.17B
Increased by 7.77%
EPS This Year
9.58
from 6.92
Increased by 38.51%
EPS Next Year
10.58
from 9.58
Increased by 10.38%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.4B | 5.9B | 6.4B | ||
| Avg | 5.2B | 5.6B | 6.0B | ||
| Low | 5.0B | 5.3B | 5.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.3% | 14.2% | 14.5% | ||
| Avg | 10.4% | 7.8% | 7.1% | ||
| Low | 6.7% | 2.8% | 1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.36 | 11.72 | 13.00 | ||
| Avg | 9.58 | 10.58 | 11.58 | ||
| Low | 8.96 | 9.80 | 10.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 49.8% | 22.3% | 22.9% | ||
| Avg | 38.5% | 10.4% | 9.5% | ||
| Low | 29.4% | 2.2% | -1.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.